CureC9 Path to Trial
CureC9 Path to Trial
A Program of EverythingALS
CureC9 and EverythingALS are part of designing the first-ever prevention trial for genetic ALS and FTD together. You can take part in a study called CureC9 Path to Trial right from home. It is open to anyone carrying the C9 gene mutation or a mutation in another gene that causes ALS or FTD, to families with ALS or FTD where the gene is not yet known, and to anyone at risk, such as a child or sibling of a person with genetic ALS or FTD, even if you haven't had any genetic testing yourself. When the prevention trial begins, or if you are living with genetic ALS or FTD and a trial becomes possible specifically for you, our team will contact you directly.
Families Fight Together. Everyone over the age of 18 in a family with genetic ALS or FTD, on both sides, can participate, and if any family members are living with ALS or FTD, they can enroll too! Spouses, partners, and family members who aren't at risk can also join as control participants to provide baseline data.
What is CureC9 Path to Trial?
CureC9 Path to Trial is an observational research study designed to build the scientific foundation and patient cohort required to launch a prevention clinical trial. The same cohort will help future treatment trials for C9 and other genetic forms of ALS and FTD find people at every stage: before symptoms, as symptoms begin, and after diagnosis.
CureC9 Path to Trial focuses on C9, but it is not limited to C9. It is open to every genetic form of ALS and FTD, including families where the gene has not yet been found.
CureC9 Path to Trial is a companion to the CureC9 Research Program. Both are EverythingALS programs to accelerate treatments and prevention options for C9orf72 ALS and FTD.
You can participate remotely at home. When you join, we will send you a watch to wear. The watch measures how you move.
Using the EverythingALS app, you record short speech tasks, which researchers analyze for early changes in speech, and you take an online cognitive test. Our goal is to add optional at-home blood draws, and we are working toward it.
You can stop your participation at any time.
When a prevention clinical trial for C9 ALS and FTD opens, the study team will contact you.
Families Fight Together
A mutation in the C9 gene (C9orf72) is the most common inherited cause of both ALS and FTD. If a parent carries this mutation, each child has a 50% chance of inheriting it.
Even within the same family, relatives with the C9 mutation can develop different conditions at different ages. By following families over time, researchers can learn which early changes are associated with ALS, which are associated with FTD, and which are part of the normal aging process.
Who can join:
- People predisposed to C9 ALS or FTD
- People living with ALS or FTD
- Carriers of other ALS or FTD genes
- Families with ALS or FTD where the gene has not yet been found
- People at risk who do not know their genetic status
- Your family members, who join as controls
A family member or caregiver can sign up on someone else's behalf.
Once the study is live, our goal is to link relatives who join to the same family.
You can take part from anywhere in the United States. EverythingALS is working to expand internationally, starting with Canada and Australia. You must be 18 or older.
Not ready to join yet? Sign up for our newsletter to hear CureC9 news, including prevention trials.
Join takes you to the EverythingALS sign-up form for The ALS Gene Carrier Study. A new CureC9 Path to Trial form is coming in the next few weeks.
Before you join
- Does it cost anything?
- No. CureC9 Path to Trial is free.
- Is there an end date?
- No. CureC9 Path to Trial is ongoing and has no time limit.
- Do I need a genetic test?
- No. You do not need to know your genetic status, and CureC9 Path to Trial does not test your genes or give you genetic results. If you are thinking about testing, a genetic counselor can help you decide. Read about genetic counseling at End the Legacy.
- Will I hear about my own results?
- Yes. You get all of your own study data. The exception is blood: once at-home blood draws are added, blood results will not be shared at this time.
- Could genetic testing affect my insurance or job?
- CureC9 Path to Trial does not test your genes, so taking part does not create genetic information about you. If you are thinking about genetic testing outside the study, as stated on the End the Legacy website, "Testing can have medical, emotional, family, privacy, and insurance implications," and "a licensed genetic counselor can help you understand the potential medical, emotional, privacy, and insurance considerations." Read more about genetic testing at End the Legacy.
- Do I need to see a doctor or get bloodwork done?
- No. Participation in CureC9 Path to Trial is entirely remote through the EverythingALS app, and there are no doctor visits. Our goal is to add optional at-home blood draws, and you can take part fully without one. Once you sign up, our team will reach out to help you set up the app and the watch.
- How much time does it take?
- Signing up takes one form. The home tasks take a few minutes a month, and not every week has tasks.
- What if I don't have a smartphone?
- You need a phone or tablet. The EverythingALS app works on most phones and tablets, and EverythingALS provides the watch.
- Who sees my data?
- Your data is held by EverythingALS under its privacy policy.
- Who can I talk to?
- Questions about the study: silviya@everythingals.org. To meet other families with genetic ALS and FTD: End the Legacy. Anything else: the CureC9 contact form.
How it works
- Fill out the sign-up form. It takes a few minutes.
- The EverythingALS team contacts you to set up the app and sends you the watch.
- You wear the watch, record short speech tasks and take an online cognitive test at home on your own schedule. The tasks take a few minutes a month.
- When a prevention trial opens, the EverythingALS team contacts you. You decide whether to take part.
Why remote monitoring
CureC9's Scientific Advisory Board has started planning a prevention trial for genetic ALS and FTD, and measurements taken at home could be part of it.
The third CureC9 Scientific Advisory Board meeting convened on September 18, 2026, with added experts and community representatives, and voted unanimously to create a working group on prevention. The consensus was a platform prevention trial for genetic ALS and FTD. Planning is in the initial stages, details to follow.
A prevention trial has to measure change before symptoms appear, and frequent clinic visits are a burden for people without symptoms. EverythingALS already measures speech, breathing, movement and thinking at home, and asks people how they are doing, all of which could be used in a prevention trial.
Support this program
Fund CureC9 Path to Trial
Gifts go through EverythingALS and fund CureC9 Path to Trial, so we can expand the study to as many people as possible. On the EverythingALS CureC9 donation page, please earmark your gift for "CureC9 Path to Trial."
Gifts to CureC9 Path to Trial are tax-deductible. EverythingALS is a brand of Peter Cohen Foundation, a non-profit 501(c)(3): EIN 84-3055901. CureC9 Path to Trial is a program of EverythingALS.
For companies developing C9orf72 therapies
Companies with C9orf72 targets in development can contribute to the development of a prevention trial cohort and registry by requesting a customized EverythingALS consortium packet. This is another way to support CureC9 Path to Trial financially.
Donate cells
Patients can donate cells for research through the C9orf72 Stem Cell Bank.
Not ready to join yet? Sign up for our newsletter to hear CureC9 news, including prevention trials.